Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30546511 | 1.00 | L3MBTL1 (0.48) | L3MBTL1NR4A2CDK1ALDH1A1GAA | |
| SCHEMBL1369472 | 0.87 | NR4A2 (0.48) | L3MBTL1NR4A2CDK1ALDH1A1GAA | |
| SCHEMBL19202355 | 0.85 | CA2 (0.61) | L3MBTL1NR4A2CDK1ALDH1A1GAA | |
| SCHEMBL1557539 | 0.85 | L3MBTL1 (0.47) | L3MBTL1NR4A2CDK1ALDH1A1GAA | |
| SCHEMBL22827685 | 0.84 | MAPT (0.46) | L3MBTL1NR4A2CDK1ALDH1A1GAA | |
| SCHEMBL21027865 | 0.81 | VCAM1 (0.61) | L3MBTL1CDK1ALDH1A1GAAVCAM1 | |
| SCHEMBL26580541 | 0.81 | KDM4E (0.52) | ALDH1A1CA2CA1CA5ACA9 | |
| SCHEMBL1110811 | 0.80 | CDK1 (0.48) | CDK1VCAM1HSD17B10SLC6A3CA2 | |
| SCHEMBL1017485 | 0.80 | ABL1 (0.54) | NR4A2CDK1VCAM1SLC6A3CA2 | |
| SCHEMBL29773857 | 0.78 | NR4A2 (0.56) | L3MBTL1NR4A2ALDH1A1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107424-A1 | N-(4-(IMIDAZO[4,5-B]PYRIDIN-5-YL)-2-PYRIDYL)BENZAMIDE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107418-A1 | N-(4-(1H-BENZO[D[IMIDAZOL-6-YL)-PYRIDIN-2-YL)BENZAMIDE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107420-A1 | N-(4-(1H-BENZO[D[IMIDAZOL-6-YL)-PYRIDIN-2-YL)BENZAMIDE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4037687-B1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | MOLECULAR SKIN THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12281123-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | ML Bio Solutions Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | ML Bio Solutions Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | ML Bio Solutions Inc. | 2024-02-29 | — | — | US | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4037687-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | Molecular Skin Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114615984-A | Benzoxazinone compounds as KLK5/7 dual inhibitors | 分子皮肤治疗公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021067335-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210101911-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2021-04-08 | — | — | US | disclosed |
| WO-2021067335-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210101911-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2021-04-08 | — | — | US | disclosed |
| EP-2417121-A1 | 4, 5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | Pfizer Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010116282-A1 | 4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281123-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | KLK5, KLK1, KLK2 | L3MBTL1 4580/4885NR4A2 2179/4885CDK1 640/4885 |
| US-20210101911-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | KLK5, KLK1, KLK2 | L3MBTL1 4580/4885NR4A2 2179/4885CDK1 640/4885 |
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | KLK5, KLK1, KLK2 | L3MBTL1 4580/4885NR4A2 2179/4885CDK1 640/4885 |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | KLK5, KLK1, KLK2 | L3MBTL1 4580/4885NR4A2 2179/4885CDK1 640/4885 |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NR3C2, REN, AGTR1 | L3MBTL1 4869/4885NR4A2 127/4885CDK1 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.